Products - Amgen
Amgen’s medicines treat serious illnesses and typically address diseases with a limited number of treatment options. With a presence in approximately 100 countries, we are proud to have reached millions of people with our products.
Amgen - Wikipedia
Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. [3][4] One of the world's largest independent biotechnology companies, As of 2022, Amgen has approximately 24,000 staff in total. [5]
Amgen | A Worldwide Pioneer in Biotechnology
Amgen is a pioneer in the science of using living cells to make biologic medicines. READ MORE. Our Products. Amgen’s medicines treat serious illnesses and typically address diseases with a limited number of treatment options. READ MORE.
FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY ... - Amgen
May 16, 2024 · IMDELLTRA™ (tarlatamab-dlle) is indicated for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. This indication is approved under accelerated approval based on overall response rate and duration of response.
FDA Approves Amgen Drug for Persistently Deadly Form of Lung …
May 16, 2024 · The drug tarlatamab, or Imdelltra, made by the company Amgen, tripled patients’ life expectancy, giving them a median survival of 14 months after they took the drug. Forty percent of those...
Advancing Oncology at the Speed of Life | Amgen Oncology
At Amgen we are committed to changing the course of cancer treatment for more than 40 years. Learn about all of the different Amgen Oncology web propoerties and resources that Amgen has to offer.
Amgen Pipeline
Amgen Pipeline. Download pipeline chart. A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.
Amgen overcomes historically undruggable target, with FDA …
Jun 1, 2021 · The FDA has approved Amgen’s sotorasib, a first-in-class KRAS-G12C inhibitor, for non-small-cell lung cancer (NSCLC). The KRAS oncoprotein is mutated in up to 25% of cancers and carries a...
FDA approves Amgen drug for tough-to-treat form of lung cancer
May 17, 2024 · The Food and Drug Administration on Thursday granted accelerated approval to a new dual-acting drug from Amgen to treat small cell lung cancer in people whose disease has progressed following chemotherapy.
FDA approves Amgen drug for lung cancer with specific mutation
May 28, 2021 · The U.S. Food and Drug Administration on Friday approved an Amgen Inc drug for non-small cell lung cancer with a specific mutation in a gene known as KRAS in patients whose disease has worsened...